Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06581198 · ClinicalTrials.gov registry record · Phase 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

A Phase 2 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
179
Enrollment target
20
Study locations

NCT06581198 is a Phase 2 study of Lupus Nephritis and Lupus Erythematosus, Systemic that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 179 participants, below the 304-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06581198, a Phase 2 study of Lupus Nephritis and Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
179 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Conditions Studied

Lupus Nephritis Lupus Erythematosus, Systemic

Interventions

  • BIOLOGICAL rapcabtagene autoleucel

Study Locations (20)

California

  • Loma Linda University - San Bernardino
  • UCSF - San Francisco
  • UCSF - San Francisco
  • Sutter Health Network - San Pablo

Illinois

  • Ann and Robert H Lurie Childs Hosp - Chicago
  • Northwestern University - Chicago

Massachusetts

  • Tufts Medical Center - Boston
  • Boston Medical Center - Boston

Texas

  • Univ Of TX MD Anderson CC - Houston
  • University of Texas MD Anderson Cancer Center - Houston

Utah

  • LDS Hospital - Salt Lake City
  • LDS Hospital - Salt Lake City

Other

  • Novartis Investigative Site - Graz
  • Novartis Investigative Site - Vienna

Alabama

  • University Of Alabama - Birmingham

Iowa

  • University Of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 179 participants
Start Date 2024-09-04
Est. Completion 2032-02-06
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06581198

The ClinicalTrials.gov registry entry for NCT06581198 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (41% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which rapcabtagene autoleucel is the first listed.

NCT06581198 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06581198 about?

NCT06581198 is a clinical study titled "A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)". The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

What is the current status of trial NCT06581198?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2024-09-04. Estimated completion is 2032-02-06.

What conditions does trial NCT06581198 study?

This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic.

What interventions are being tested in trial NCT06581198?

The interventions under investigation include: rapcabtagene autoleucel (BIOLOGICAL).

Who is sponsoring clinical trial NCT06581198?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06581198 being conducted?

This trial has 20 study locations across Alabama, California, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Nephritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Nephritis

All registered trials for this condition

Lupus Erythematosus, Systemic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.